Related Experiment Video
Updated: Nov 16, 2025

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
[Efficacy of Tranexamic Acid to decrease perioperative bleeding in primary total reverse arthroplasty]
R B Palmieri-Bouchan1, V H Aguirre-Rodríguez1, L E Salinas-Vela1
1Alta Especialidad en Cirugía de Reconstrucción Articular de Hombro y Codo. Facultad Mexicana de Medicina de la Universidad La Salle. Hospital Ángeles Pedregal, GASS. México.
Introduction:
Reverse shoulder arthroplasty improves function and pain in patients with glenohumeral osteoarthritis and rotator cuff deficiency. However, it is associated with significant blood loss and postoperative hematoma (PO) formation.
Objective:
To determine the efficacy of tranexamic acid (ATXM) to decrease perioperative bleeding in patients undergoing primary reverse shoulder arthroplasty.
Material And Methods:
Cohort of 31 patients undergoing reverse primary arthroplasty, in two groups: group A (17 patients) were given 1 g IV of preoperative tranexamic acid and group B (14 patients) to whom it was not administered. Preoperative hemoglobin and hematocrit were recorded and then after 24 hours of surgery, and quantified bleeding in drainage at 24 hours, as well as blood transfusion needs. The changes presented were statistically compared.
Results:
Demographic data did not show significant differences between the two groups. There is a tendency to reduce bleeding in surgical drainage in patients with ATXM (115.6 ml vs. 162.65 ml p = 0.0768), in the decrease of hemoglobin (2.16 g/dl vs. 2.79 g/dl p = 0.1257) and hematocrit (6.67% vs. 7.95% p = 0.3431). There was a significant reduction in the use of blood products in patients with ATXM (p = 0.0441).
Conclusion:
There is a tendency to have less PO bleeding in patients undergoing primary reverse arthroplasty with the use of ATXM and a lower PO blood transfusion requirement.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

